22 June 2023 
EMA/281506/2023  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Jardiance 
empagliflozin 
On 22 June 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Jardiance. The marketing authorisation holder for this medicinal product is Boehringer Ingelheim 
International GmbH. 
The CHMP adopted a new indication for the treatment of chronic kidney disease. For information, the full 
indications for Jardiance will be as follows:2 
Type 2 diabetes mellitus 
Jardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes 
mellitus as an adjunct to diet and exercise 
- 
- 
as monotherapy when metformin is considered inappropriate due to intolerance 
in addition to other medicinal products for the treatment of diabetes 
Heart failure 
Jardiance is indicated in adults for the treatment of symptomatic chronic heart failure. 
Chronic kidney disease 
Jardiance is indicated in adults for the treatment of chronic kidney disease. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
 
 
